口服可溶型环氧化物水解酶/磷酸二酯酶 4 双重抑制剂治疗炎症性疼痛。
Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
机构信息
Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center , University of California Davis , One Shields Avenue , Davis , California 95616 , United States.
Department of Pharmacology , University of California Davis , One Shields Avenue , Davis , California 95616 , United States.
出版信息
J Med Chem. 2018 Apr 26;61(8):3541-3550. doi: 10.1021/acs.jmedchem.7b01804. Epub 2018 Apr 10.
Abstract
Inspired by previously discovered enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA). In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood ( T = 30 min; C = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h. Additionally, MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.
摘要
受先前发现的可溶性环氧化物水解酶 (sEH) 和磷酸二酯酶 4 (PDE4) 抑制剂之间增强的镇痛疗效的启发，我们设计、合成并表征了 21 种新型 sEH/PDE4 双重抑制剂。其中最好的一种在体外试验中显示出良好的疗效。进一步对 4 种选定化合物的一部分进行药代动力学研究，确定了一种可生物利用的双重抑制剂 N-(4-甲氧基-2-(三氟甲基)苄基)-1-丙酰基哌啶-4-甲酰胺 (MPPA)。在脂多糖诱导的炎性疼痛大鼠模型中，MPPA 在口服 3 mg/kg 后迅速在血液中增加（T = 30 分钟；C = 460 nM），并在 4 小时的时间过程中与血液水平相关，具有快速作用开始的抗炎性疼痛。此外，MPPA 不会改变炎性疼痛大鼠的自发探索或对照大鼠的退缩潜伏期。
相似文献
1
Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.口服可溶型环氧化物水解酶/磷酸二酯酶 4 双重抑制剂治疗炎症性疼痛。
J Med Chem. 2018 Apr 26;61(8):3541-3550. doi: 10.1021/acs.jmedchem.7b01804. Epub 2018 Apr 10.
2
Design and Synthesis of sEH/HDAC6 Dual-Targeting Inhibitors for the Treatment of Inflammatory Pain.设计和合成 sEH/HDAC6 双重靶向抑制剂治疗炎性疼痛。
J Med Chem. 2024 Aug 8;67(15):12887-12911. doi: 10.1021/acs.jmedchem.4c00847. Epub 2024 Jul 21.
3
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.在糖尿病性神经病变小鼠模型中，可溶性环氧化物水解酶抑制具有抗伤害感受作用。
J Pain. 2014 Sep;15(9):907-14. doi: 10.1016/j.jpain.2014.05.008. Epub 2014 Jun 9.
4
Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models.3 种可溶性环氧化物水解酶抑制剂在大鼠神经病理性和炎性疼痛模型中的比较疗效。
Eur J Pharmacol. 2013 Jan 30;700(1-3):93-101. doi: 10.1016/j.ejphar.2012.12.015. Epub 2012 Dec 28.
5
Facile synthesis of carbon-11-labeled sEH/PDE4 dual inhibitors as new potential PET agents for imaging of sEH/PDE4 enzymes in neuroinflammation.碳-11标记的可溶性环氧化物水解酶/磷酸二酯酶4双重抑制剂的简便合成作为用于神经炎症中可溶性环氧化物水解酶/磷酸二酯酶4酶成像的新型潜在正电子发射断层显像剂。
Bioorg Med Chem Lett. 2019 Jul 1;29(13):1654-1659. doi: 10.1016/j.bmcl.2019.04.036. Epub 2019 Apr 25.
6
A Soluble Epoxide Hydrolase Inhibitor Improves Cerebrovascular Dysfunction, Neuroinflammation, Amyloid Burden, and Cognitive Impairments in the hAPP/PS1 TgF344-AD Rat Model of Alzheimer's Disease.一种可溶性环氧化物水解酶抑制剂可改善阿尔茨海默病hAPP/PS1转基因F344-AD大鼠模型中的脑血管功能障碍、神经炎症、淀粉样蛋白负荷和认知障碍。
Int J Mol Sci. 2025 Mar 8;26(6):2433. doi: 10.3390/ijms26062433.
7
Potent soluble epoxide hydrolase inhibitors based on thiazole-5-carboxamide structure with imidazolidinone moiety as a secondary pharmacophore.基于噻唑-5-甲酰胺结构并以咪唑烷酮部分作为二级药效团的强效可溶性环氧化物水解酶抑制剂。
Bioorg Chem. 2025 Aug;163:108644. doi: 10.1016/j.bioorg.2025.108644. Epub 2025 May 29.
8
Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales.十字花目植物中基于尿素的可溶性环氧化物水解酶抑制剂的存在情况。
PLoS One. 2017 May 4;12(5):e0176571. doi: 10.1371/journal.pone.0176571. eCollection 2017.
9
Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice.可溶性环氧化物水解酶抑制可减轻阿基塔（Ins2 Akita）小鼠的神经病变。
Behav Brain Res. 2017 May 30;326:69-76. doi: 10.1016/j.bbr.2017.02.048. Epub 2017 Mar 1.
10
Inhibition of Soluble Epoxide Hydrolase Prevents Docetaxel-Induced Painful Peripheral Neuropathy.抑制可溶性环氧化物水解酶可预防多西他赛诱导的疼痛性周围神经病变。
Int J Mol Sci. 2025 Jun 12;26(12):5630. doi: 10.3390/ijms26125630.
引用本文的文献
1
Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.发现美金刚脲衍生物作为有效的可溶性环氧化物水解酶抑制剂可对抗脂多糖诱导的败血症。
Eur J Med Chem. 2021 Nov 5;223:113678. doi: 10.1016/j.ejmech.2021.113678. Epub 2021 Jun 29.
2
Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016.正电子发射断层扫描技术用于环核苷酸磷酸二酯酶成像的挑战：2016年以来的新型放射性配体及（临床前）研究洞察
Int J Mol Sci. 2021 Apr 7;22(8):3832. doi: 10.3390/ijms22083832.
3
Inhibition of the Soluble Epoxide Hydrolase as an Analgesic Strategy: A Review of Preclinical Evidence.抑制可溶性环氧化物水解酶作为一种镇痛策略：临床前证据综述
J Pain Res. 2021 Jan 13;14:61-72. doi: 10.2147/JPR.S241893. eCollection 2021.
4
Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.小分子可溶环氧化物水解酶抑制剂在炎症和癌症的多靶点和联合治疗中的应用。
Molecules. 2020 Nov 24;25(23):5488. doi: 10.3390/molecules25235488.
5
Lack of rewarding effects of a soluble epoxide hydrolase inhibitor TPPU in mice: Comparison with morphine.可溶性环氧化物水解酶抑制剂 TPPU 在小鼠中缺乏奖赏效应：与吗啡的比较。
Neuropsychopharmacol Rep. 2020 Dec;40(4):412-416. doi: 10.1002/npr2.12136. Epub 2020 Sep 7.
6
Epoxy Fatty Acids Are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation.环氧脂肪酸是治疗疼痛、心血管疾病和其他以线粒体功能障碍、内质网应激和炎症为特征的疾病的有前途的靶点。
Adv Exp Med Biol. 2020;1274:71-99. doi: 10.1007/978-3-030-50621-6_5.
7
Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP).新型小分子衍生的成纤维细胞活化蛋白（FAP）高选择性底物
ACS Med Chem Lett. 2019 Jul 9;10(8):1173-1179. doi: 10.1021/acsmedchemlett.9b00191. eCollection 2019 Aug 8.
本文引用的文献
1
Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.用于阿尔茨海默病的 I 期和 II 期临床试验的研究性磷酸二酯酶抑制剂。
Expert Opin Investig Drugs. 2017 Sep;26(9):1033-1048. doi: 10.1080/13543784.2017.1364360. Epub 2017 Aug 9.
2
Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit.可溶性环氧化物水解酶抑制剂UC1728对兔脂多糖诱导性葡萄膜炎的作用
J Ocul Biol. 2016 Jan;4(1). doi: 10.13188/2334-2838.1000024. Epub 2016 Jan 12.
3
Design, Synthesis and Cellular Characterization of a Dual Inhibitor of 5-Lipoxygenase and Soluble Epoxide Hydrolase.5-脂氧合酶和可溶性环氧化物水解酶双重抑制剂的设计、合成及细胞特性研究
Molecules. 2016 Dec 29;22(1):45. doi: 10.3390/molecules22010045.
4
cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor.未接受药物治疗的抑郁症患者大脑中的环磷酸腺苷（cAMP）信号传导减少，而使用选择性5-羟色胺再摄取抑制剂进行治疗后该信号传导增加。
Mol Psychiatry. 2017 May;22(5):754-759. doi: 10.1038/mp.2016.171. Epub 2016 Oct 11.
5
Genetically Encoded Biosensors Reveal PKA Hyperphosphorylation on the Myofilaments in Rabbit Heart Failure.基因编码生物传感器揭示兔心力衰竭时肌丝上蛋白激酶A的过度磷酸化
Circ Res. 2016 Sep 30;119(8):931-43. doi: 10.1161/CIRCRESAHA.116.308964. Epub 2016 Aug 30.
6
Substituted 4-morpholine N-arylsulfonamides as γ-secretase inhibitors.取代 4-吗啉 N-芳基磺酰胺类化合物作为 γ-分泌酶抑制剂。
Eur J Med Chem. 2016 Nov 29;124:36-48. doi: 10.1016/j.ejmech.2016.08.024. Epub 2016 Aug 13.
7
Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress.可溶性环氧化物水解酶的基因缺陷和药理抑制赋予对反复社会挫败应激的恢复力。
Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1944-52. doi: 10.1073/pnas.1601532113. Epub 2016 Mar 14.
8
Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.新型可溶性环氧水解酶抑制剂GSK2256294的药代动力学、药效学及不良事件概况
Br J Clin Pharmacol. 2016 May;81(5):971-9. doi: 10.1111/bcp.12855. Epub 2016 Jan 17.
9
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators.N-苄基苯甲酰胺：一种新型口服双重环氧合酶/过氧化物酶体增殖物激活受体 γ调节剂融合支架
J Med Chem. 2016 Jan 14;59(1):61-81. doi: 10.1021/acs.jmedchem.5b01239. Epub 2015 Dec 25.
10
Uncovering the function of Disrupted in Schizophrenia 1 through interactions with the cAMP phosphodiesterase PDE4: Contributions of the Houslay lab to molecular psychiatry.通过与环磷酸腺苷磷酸二酯酶PDE4相互作用揭示精神分裂症1基因的功能：豪斯利实验室对分子精神病学的贡献
Cell Signal. 2016 Jul;28(7):749-52. doi: 10.1016/j.cellsig.2015.09.019. Epub 2015 Sep 30.
Zotero 插件